EX-FILING FEES 11 ex107.htm

 

Exhibit 107

 

Calculation of Filing Fee Tables

 

FORM S-1

(Form Type)

 

BRIACELL THERAPEUTICS CORP.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

   Security Type  Security Class Title  Fee Calculation Rule  Amount Registered   Proposed Maximum Offering Price Per Share  

Maximum Aggregate Offering

Price(1)(2)

   Fee Rate   Amount of Registration Fee 
Fees to Be Paid  Equity  Units consisting of (1)(3)  457(o)                              $11,500,000   $0.0001531   $1,760.65 
Fees to Be Paid  Equity  (i) Common Shares, no par value (5)                -    -    - 
Fees to Be Paid  Equity  (ii) One Warrant to Purchase One Common Share (4)                -    -    - 
Fees to Be Paid  Equity  Common Shares Underlying Warrants (3)                14,375,000(5)  $0.0001531    2,200.81 
Fees to Be Paid  Equity  Pre-funded Units consisting of (1)(3)                -    -    (3)
Fees to Be Paid  Equity  (i) Common Shares (4)                -    -    - 
Fees to Be Paid  Equity  (ii) Pre-Funded Warrants to Purchase Common Shares (4)                -    -    (3)
Fees to Be Paid  Equity  Common Shares Underlying Pre-Funded Warrants (3)                -    -    (3)
Fees to Be Paid  Equity  Representative’s Warrants to Purchase Common Shares                -    -    (4)
Fees to Be Paid  Equity  Common Shares Underlying Representative’s Warrants               $718,750(6)  $0.0001531   $110.04 
   Total Offering Amounts         26,593,750        $4,071.50 
   Total Fees Previously Paid         -        $- 
   Total Fee Offsets         -        $- 
   Net Fee Due                  $4,071.50 

 

(1) This registration statement also includes an indeterminate number of securities that may become offered, issuable or sold to prevent dilution resulting from stock splits, stock dividends and similar transactions, which are included pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”).
   
(2) Includes the offering price of additional Units that the underwriters have the option to purchase to cover over-allotments, if any.
   
(3) The proposed maximum aggregate offering price of the Units will be reduced on a dollar-for-dollar basis based on the offering price of any Pre-funded Units issued in the offering, and the proposed maximum aggregate offering price of the Pre-funded Units to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any Units issued in the offering. Accordingly, the proposed maximum aggregate offering price of the Units and Pre-funded Units (including the common stock issuable upon exercise of the warrants and the pre-funded warrants), if any, is $11,500,000.
   
(4) No separate registration fee is payable pursuant to Rule 457(g) under the Securities Act.
   
(5) As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the shares underlying the Warrants is equal to $14,375,000 (which is equal to the proposed maximum aggregate offering price for the Units of $11,500,000 multiplied by 125%).
   
(6) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. The warrants have an exercise price equal to 125% of the public offering price. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the shares underlying the Representative’s Warrants is equal to $718,750 (which is equal to 5% of the proposed maximum aggregate offering price for the Units of $11,500,000 multiplied by 125%).